Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients

A Randomized Controlled Trial to Evaluate the Efficacy of Reducing High-Phosphate Containing Diet Education and Proper Phosphate Binder Intake Education to Serum Phosphate Level Among Maintenance Hemodialysis Patients

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02755961

Enrollment

Registered

2016-04-29

Start date

2015-07-31

Completion date

2015-10-31

Last updated

2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage Renal Disease, Hyperphosphatemia

Keywords

End-stage renal disease, Phosphate binders, Hyperphosphatemia, Dietary education

Brief summary

Hyperphosphatemia is an independent risk factor for mortality among dialysis patients. And most phosphate in human is derived from the food. The purpose of this study is to evaluate the efficacy of nutritional consultation and education on phosphate binder among dialysis patients.

Detailed description

Hyperphosphatemia is an independent risk factor for mortality among dialysis patients. Hyperphosphatemia is associated with increased incidence of cardiovascular diseases, and is a mediator to the development of hyperparathyroidism and mineral bone disorder. Phosphate is usually obtained by food intake, and it can be removed by hemodialysis. However, the efficacy of removal is limited, so that dietary education and proper intake of phosphate binder is essential.

Interventions

BEHAVIORALDietary education

BEHAVIORALEducation on phosphate binder use

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* End-stage renal disease patients whose dialysis vintage is more than 3 months

Exclusion criteria

* Patients with liver cirrhosis * Pregnant patients * Patients with alimentary tract malabsorption diseases * History of recent alcohol or drug abuse * Patients receiving chemotherapy for solid organ tumor * History of mental illness (major depressive disorder, bipolar disorder, schizophrenia, etc.) * Patients having difficulty communicating with our medical team (dementia, mental retardation, etc.)

Design outcomes

Primary

Measure	Time frame
The proportion of patients who reached Ca x P product lower than 55	2-3 month

Secondary

Measure	Time frame
Changes of MMAS-8 score	1 month, 2-3 month
Changes of bioequivalent dose of phosphate binder	2-3 month
Changes of PG-SGA	2-3 month
Amount of change in dietary phosphorus intake	2-3 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026